Percutaneous Coronary Intervention

According to a prespecified analysis of the BASKET-SMALL 2 trial, reperfusion with a drug-coated balloon in patients with CAD and small vessels may be noninferior to a drug-eluting stent, regardless of the indication for PCI.

In patients with three-vessel CAD and/or left main disease, those with heavily calcified lesions had elevated long-term mortality risk, which did not vary by assignment to PCI or CABG, according to new data from the SYNTAXES study.

Treatment with the IV P2Y12 inhibitor cangrelor reduced the number of early ischemic events after PCI, primarily MI and stent thrombosis, compared with oral clopidogrel, according to the results of the CHAMPION PHOENIX trial.

In a cohort of patients with MI and mild or moderate chronic kidney disease, Black individuals were less likely to receive invasive management compared with their white counterparts, researchers reported.

This year, Transcatheter Cardiovascular Therapeutics was held as a hybrid meeting Nov. 4 to 6, with some participants attending in person in Orlando and others attending virtually.

Compared with the conventional transradial strategy for PCI, the distal transradial approach lowered the rate of forearm radial artery occlusion and shortened hemostasis time, according to new data.

PCI guided by quantitative flow ratio or angiography.

FFR-guided PCI or CABG in patients with three-vessel CAD.

Svelte Medical Systems announced the FDA approved two of its drug-eluting stent systems designed to facilitate transradial PCI.

Ticagrelor monotherapy after 3 months of dual antiplatelet therapy lowered the incidence of major bleeding events vs. continued DAPT among patients with high bleeding risk who underwent PCI, according to new insights from TWILIGHT.